Stay login |  Sign Up |  Find ID/Password |  FAQ

New HIV drug opens door to treat multidrug-resistant patients

페이지 정보

작성자 dermamall 작성일18-09-26 17:05 조회721회 댓글0건


Written by Man-tik Choy, Ph.D


A recent clinical study conducted by the Yale School of Medicine showed that a new HIV drug, Ibalizumab, could reduce viral replication and improve immunity in patients with multidrug-resistant HIV-1 infection. HIV-1 and HIV-2 are two distinct viruses that cause human immunodeficiency virus (HIV) infection and over time acquired immunodeficiency syndrome (AIDS). According to The Joint United Nations Programme on HIV/AIDS, there were approximately 36.7 million people worldwide living with HIV/AIDS at the end of 2016. HIV-1 is the earliest and most common HIV which accounts for almost 95% of all infections worldwide.

In a new paper published in The New England Journal of Medicine, a group of medical experts from the Yale School of Medicine in the United States combined a new drug, called ibalizumab, with existing HIV medications to treat HIV-1 infected patients for whom multiple antiretroviral therapies had failed. Slightly different from the current oral drugs, patients were receiving intravenous doses of ibalizumab for one week. This new mode of delivery is aimed at preventing HIV from entering the body immune system. This phase-3 clinical study was supported by the FDA’s Orphan Products Clinical Trials Grants Program. The researchers recruited 40 patients from multiple sites in North America and Taiwan from 2015 to 2016.


After receiving ibalizumab for one week, most of the patients experienced a remarkable reduction of HIV viral load in their blood. After half a year, nearly half of the patients found viral loads below the level of detection, and at the same time, their immune strengths were significantly improved. Also, there were no clinical differences in efficacy across the age, sex, or race of the patients. This exciting finding opens new doors to reshape the future therapy for multidrug-resistant HIV patients who have run out of effective treatment options. Further thorough research on the associated side effects and adverse events is still needed before we can conclude that this new HIV drug is safe and effective.


Click for full article


등록된 댓글이 없습니다.

To the Main Page
About Dermamall   Conditions of Use   Privacy Policy   Contact Us TOP

Company Name DERMAMALL Address 7F, Lime T/W 325, Bongeunsa-ro, Gangnam-gu, seoul
Business Registration Number 314-81-37759 CEO Ro Young Woo Tel +82)2-549-7999 Fax +82)2-544-0306
Copyright © 2001-2013 DERMAMALL. All Rights Reserved.